Breast cancer (Tokyo, Japan)最新文献

{"title":"Risk of developing subsequent primary breast cancer among non-breast cancer survivors: a retrospective cohort study.","authors":"Yibing Ruan, Hannah Harsanyi, Matthew T Warkentin, Huiming Yang, Sasha Lupichuk, Patricia A Tang, Kareem Jamani, Robert J Hilsden, Darren R Brenner, Winson Y Cheung, Dylan E O'Sullivan","doi":"10.1007/s12282-026-01880-1","DOIUrl":"10.1007/s12282-026-01880-1","url":null,"abstract":"<p><strong>Background: </strong>Cancer survivors have an elevated risk of developing subsequent primary cancer, with breast cancer being one of the most common sites. Our study aimed to determine the incidence, patterns of, and risk factors for diagnosis of a subsequent primary breast cancer (SPBC) among survivors of adult non-breast cancers.</p><p><strong>Methods: </strong>Adult females diagnosed with a non-breast cancer in Alberta, Canada between 2000 and 2021 who survived ≥ 180 days were followed until SPBC diagnosis, death, or censoring on December 31, 2021. The incidence of SPBC was compared to the cancer-free general population using standardized incidence ratios (SIRs) and incidence rate differences (IRDs). Exploratory analyses of the association between sociodemographic/clinical factors and SPBC risk was conducted according to cancer type using Fine-Gray models adjusting for competing risk of death.</p><p><strong>Results: </strong>The study included 59,687 female cancer survivors, with 1113 incident SPBC cases. Overall, there was an increased risk of SPBC among survivors compared to the cancer-free general population (SIR = 1.15 [95% CI: 1.09-1.22], 10-year cumulative incidence = 2.0%). Significantly elevated SPBC risk was found among survivors of kidney, endometrial, and colorectal cancers, as well as obesity-related cancers combined. The increased risk of SPBC was primarily driven by early-stage and hormone receptor positive diagnoses. Depending on the primary cancer site, risk factors for SPBC included overweight/obese body mass index, diabetes, and cancer treatment.</p><p><strong>Conclusions: </strong>History of cancer should prompt discussion of breast cancer awareness, screening, and risk reduction. Future research is needed to inform personalized risk assessment for survivors of adult non-breast cancers.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"1082-1092"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148261305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial.","authors":"Takashi Yamanaka, Joohyuk Sohn, Kazuki Sudo, Hirofumi Mukai, Naohito Yamamoto, Chi-Feng Chung, Yen-Shen Lu, Kyung-Hun Lee, Soo-Chin Lee, Tsutomu Iwasa, Hiroji Iwata, Kenichi Watanabe, Kyung Hae Jung, Yuko Tanabe, Seok Yun Kang, Hiroyuki Yasojima, Kenjiro Aogi, Eriko Tokunaga, Sung Hoon Sim, Yoon Sim Yap, Koji Matsumoto, Ling-Ming Tseng, Yoshiko Umeyama, Emi Noguchi, Tomomi Hata, Aya Kuchiba, Taro Shibata, Kenichi Nakamura, Yasuhiro Fujiwara, Kenji Tamura, Kan Yonemori","doi":"10.1007/s12282-026-01865-0","DOIUrl":"10.1007/s12282-026-01865-0","url":null,"abstract":"<p><strong>Background: </strong>In the Asian international PATHWAY trial, palbociclib-tamoxifen demonstrated improved progression-free survival compared with placebo-tamoxifen in patients with HR+/HER2- locally advanced or metastatic breast cancer (ABC). This analysis compared quality of life (QoL) between treatment arms.</p><p><strong>Methods: </strong>Pre/peri or postmenopausal women with HR+/HER2- ABC were randomly assigned 1:1 to receive palbociclib-tamoxifen or placebo-tamoxifen. Patient-reported outcomes were assessed on day 1 of cycles 1 (baseline), 4, and 7, and at the end of treatment (EOT) using the EORTC QLQ-C30 and QLQ-BR23 questionnaires. Least-square mean (LSM) changes in scores from baseline were calculated. Kaplan-Meier method was used to calculate time to deterioration (TTD) in the minimally important difference (MID) in the pain subscale.</p><p><strong>Results: </strong>In the comparison between treatment arms, no significant differences were observed in LSM changes in scores from baseline in global QoL (cycle 4: 0.70 [95% confidence interval (CI): -5.00, 6.41]; cycle 7: 2.17 [95% CI: -4.14, 8.48]; EOT: -5.19 [95% CI: -11.64, 1.26]). For both the EORTC QLQ-C30 and QLQ-BR23 functional and symptom subscales, no clinically meaningful differences between treatment arms were found in the LSM changes in scores from baseline. Median TTD in the MID in the pain subscale was 32.5 months (95% CI: 11.7, not estimable) for the palbociclib-tamoxifen arm and 21.2 months (95% CI: 5.5, 43.5) for the placebo-tamoxifen arm (hazard ratio = 0.729 [95% CI: 0.467, 1.138]).</p><p><strong>Conclusions: </strong>The combination of palbociclib and tamoxifen delayed deterioration in patients' QoL while they experienced reduced risk for disease progression.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov: NCT03423199; study registration date: February 6, 2018.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"991-1003"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13522070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148311143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BRCA pathogenic variants and response in early TNBC patients treated with neoadjuvant pembrolizumab: outcomes of the BRCAPATH study.","authors":"Bogdan-Valentin Popescu, Lucie Simon, Céline Blaye, Sophie Marchi, Aurélien Flèche, Sophie Gau, Fatma Guermazi, Alma Stancu, Benoîte Mery, Jean-Marc Limacher, Erion Dobi, Marianne Leheurteur","doi":"10.1007/s12282-026-01878-9","DOIUrl":"10.1007/s12282-026-01878-9","url":null,"abstract":"<p><strong>Background: </strong>Current data on BRCA status and response to neoadjuvant pembrolizumab plus chemotherapy are limited. This study evaluated the association between BRCA status and pathological complete response (pCR) in patients with early triple-negative breast cancer (TNBC).</p><p><strong>Methods: </strong>BRCAPATH was a French multicenter retrospective study including 288 patients with early TNBC; 234 received neoadjuvant pembrolizumab plus chemotherapy and 54 received chemotherapy alone. pCR was defined as ypT0/TisN0 (TNM 8th edition). Associations between BRCA status and pCR were evaluated using Fisher's exact test and multivariable logistic regression. Survival was analyzed using the Kaplan-Meier method.</p><p><strong>Results: </strong>In the pembrolizumab-treated cohort, 35 patients (15.0%) carried BRCA pathogenic variants (PV) and pCR was achieved in 88.6% of BRCA PV carriers versus 52.1% of non-carriers (p < 0.001). In multivariable analysis, BRCA PV remained independently associated with pCR (OR 8.47, 95% CI 2.65-27.04; p < 0.001). In exploratory subgroup analyses, BRCA1 pathogenic variants remained significantly associated with pCR, whereas findings for BRCA2 were limited by the small number of carriers. No statistically significant survival difference was observed for BRCA PV carriers.</p><p><strong>Conclusion: </strong>BRCA PV, particularly BRCA1, were strongly associated with pCR in pembrolizumab-treated early TNBC. These findings should be considered hypothesis-generating and warrant confirmation in larger prospective cohorts.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"1059-1069"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148261315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast ultrasound screening in young adult women undergoing infertility treatment at an infertility clinic: a retrospective observational study.","authors":"Kanako Nakano, Tadahiko Shien, Hiroyoshi Doihara, Yuko Takahashi, Reina Maeda, Marie Saji, Rei Hirata, Motomi Yukawa, Shizuka Okuda, Miyu Hirano, Toshihiro Habara, Nobuyoshi Hayashi","doi":"10.1007/s12282-026-01884-x","DOIUrl":"10.1007/s12282-026-01884-x","url":null,"abstract":"<p><strong>Background: </strong>Young adult women are increasingly undergoing infertility treatment; however, evidence regarding breast cancer screening in this population remains limited. Given that most women in this age group have dense breast tissue, for which mammography has limited sensitivity, breast ultrasound (US) is often used as a screening modality. A diagnosis of breast cancer during infertility treatment may affect both oncologic management and reproductive planning. This study aimed to examine the clinical relevance of breast US in women in their 30s undergoing infertility treatment at an infertility clinic.</p><p><strong>Methods: </strong>We retrospectively analyzed 1,336 women aged 30-39 years who underwent screening breast US between November 1, 2018, and June 30, 2025. Analyses were performed on a per-woman basis, including only the first screening examination for each participant. Breast composition was categorized according to the BI-RADS 5th edition Atlas. Screening outcomes-including recall rate, positive predictive value (PPV), cancer detection rate, and US findings (mass and non-mass findings)-were assessed using medical records. The continuation of infertility treatment, defined as ongoing or resumed treatment during the diagnostic evaluation period, was descriptively evaluated as part of the clinical context.</p><p><strong>Results: </strong>Of the 1,336 women, 1,277 (95.6%) were classified as having dense breasts. A total of 140 (10.5%) women were recalled for further evaluation. In these recalled cases, 147 findings were identified, comprising 113 mass lesions (76.8%) and 34 non-mass findings (23.1%). Four breast cancers were identified, corresponding to a cancer detection rate of 0.30% and a PPV of 2.86%. Histological diagnoses included one mucinous carcinoma, two invasive carcinomas of no special type (NST), and one ductal carcinoma in situ (DCIS). Following diagnostic evaluation, 124 recalled women (88.6%) continued infertility treatment.</p><p><strong>Conclusions: </strong>Breast US screening in women in their 30s undergoing infertility treatment provides descriptive findings within a specific clinical setting. The observed cancer detection rate appears to be within the range reported in previous studies; however, direct comparisons are limited due to differences in study populations and clinical contexts. The clinical course following recall was described as part of the screening pathway. Further prospective and multicenter studies are required to clarify the clinical significance of breast US screening in this population.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"1093-1101"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13521961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148311168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initial activities and prospects of MIRAY1: a youth-driven, society-endorsed initiative to cultivate future breast cancer physicians.","authors":"Hiroko Masuda, Takaaki Konishi, Mai Onishi, Aki Ito, Kazunoshin Tachibana, Akari Murakami, Atsushi Fushimi, Ryota Otsubo, Haruru Kotani, Yuri Kimura, Yuka Inoue, Yukinori Ozaki, Kaori Tane, Tsutomu Iwasa, Yuko Takahashi, Yuko Kanemoto, Yurika Iida, Chiaki Kudo, Sayuka Nakayama, Takahiro Suzuki, Midori Morita, Riko Sato, Masafumi Iida, Akihiko Ozaki, Mai Kitazawa, Masafumi Inokuchi, Chikako Yamauchi, Takanobu Ishida, Norikazu Masuda, Masakazu Toi","doi":"10.1007/s12282-026-01887-8","DOIUrl":"10.1007/s12282-026-01887-8","url":null,"abstract":"<p><p>Although the incidence of breast cancer is increasing rapidly in Japan, the number of specialized physicians remains insufficient, threatening the sustainability and geographic equity of care delivery. This growing mismatch between clinical demand and workforce capacity reflects not only numerical shortages, but also structural weaknesses in training, retention, and career development pathways. To address these workforce challenges, the Japanese Breast Cancer Society launched the Multi Institutional bReast cAncer Young team No.1 (MIRAY1) as a youth-driven, society-endorsed initiative focused on recruitment, education, and career development of future breast cancer specialists. MIRAY1 employs an innovative matrix structure where members belong to both one of six task groups and one of seven regional divisions. Each task group is designed to address specific challenges identified in the current breast cancer workforce pipeline; for example, limited early exposure, attrition during early and mid-career stages, and declining international mobility. Early activities have demonstrated high engagement among medical students and young physicians through hands-on education, digital communication, and peer-led networking. MIRAY1 represents a potentially sustainable workforce development model not only for Japan but also for other Asian countries facing similar challenges in oncology care.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"954-963"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148475567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness of mammography-based breast cancer screening in Jordan: a healthcare system perspective.","authors":"Shoroq M Altawalbeh, Maha Gharaibeh, Lelyan Alothman, Angela R Wateska, Kenneth J Smith","doi":"10.1007/s12282-026-01904-w","DOIUrl":"10.1007/s12282-026-01904-w","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is the most common cancer among women in Jordan, with many cases detected at advanced stages, leading to higher costs and poorer outcomes. Despite mammography's proven benefits for early detection, its use remains low. This study evaluates the cost-effectiveness and budget impact of implementing mammography screening in Jordan's healthcare system.</p><p><strong>Methods: </strong>A cost-effectiveness analysis was conducted from the perspective of the Jordanian healthcare system, comparing mammography-based screening with no screening (opportunistic detection) among women ≥ 40 years. A Markov model estimated disease progression, costs, and quality-adjusted life years (QALYs), using primarily local/regional data, supplemented by international sources when necessary. Results were expressed as incremental cost-effectiveness ratios (ICERs), i.e., cost per QALY gained. Sensitivity analyses tested model robustness. A budget impact analysis (BIA) assessed the financial implications of implementing nationwide screening.</p><p><strong>Results: </strong>Comparing mammography-based screening with no screening among women ≥ 40 years, ICER was estimated at $5341 per QALY gained, which is well below Jordan's willingness-to-pay threshold. Over a lifetime horizon, mammography screening among eligible women aged 40-50 years was projected to prevent 779 breast cancer deaths. Both one-way and probabilistic sensitivity analyses confirmed the robustness of the base-case results under uncertainty. Over five years, nationwide screening yielded net savings of $17.6 million compared to current screening estimates.</p><p><strong>Conclusion: </strong>Mammography-based breast cancer screening appears to be a cost-effective strategy in Jordan, with potential to reduce breast cancer mortality. These findings suggest possible improvements in population health outcomes and more efficient use of healthcare resources.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"1227-1236"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148687577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Next-generation endocrine therapy in HR+/HER2 - breast cancer: oral SERDs, ER-targeting innovations, and ctDNA-driven ESR1 mutation-guided switching.","authors":"Nan Yao, Guoshuai Xu, Ning Duan, Fuzhou Han, Wenqiang Li, Jun Qu","doi":"10.1007/s12282-026-01900-0","DOIUrl":"10.1007/s12282-026-01900-0","url":null,"abstract":"<p><strong>Background: </strong>Endocrine therapy (ET) is the backbone of HR+/HER2 - breast cancer management, yet acquired resistance commonly emerges despite aromatase inhibitors (AIs) and CDK4/6 inhibitors. A key actionable mechanism is treatment-selected ESR1 mutation, detectable in circulating tumor DNA (ctDNA) before radiographic progression.</p><p><strong>Scope of review: </strong>This narrative review summarizes (i) next-generation estrogen receptor (ER)-targeting agents (oral SERDs and novel ER degraders), (ii) the rationale for ESR1-guided endocrine switching, and (iii) practical considerations for implementing a ctDNA-enabled \"monitor-trigger-switch\" strategy in routine care.</p><p><strong>Key content: </strong>Oral SERDs are moving from late-line salvage toward earlier settings, supported by post-CDK4/6 efficacy signals in ESR1-mutant disease and by prospective molecular switching trials. PADA-1 and SERENA-6 provide prospective evidence that intervention at molecular progression can delay radiographic progression in selected patients. However, available SERENA-6 data remain interim, OS is immature, and implementation outside trial settings requires careful attention to assay validity, monitoring burden, cost, and risk of overtreatment from ambiguous low-level ctDNA findings. We also discuss early-stage implications, including emerging signals that adjuvant oral SERDs may improve invasive disease-free survival, raising questions regarding patient selection and integration with existing escalation strategies.</p><p><strong>Conclusions: </strong>ctDNA-enabled, ESR1-guided switching has the potential to shift endocrine management from reactive treatment changes at clinical progression toward earlier molecular interception of resistance in selected patients.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"978-990"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148687557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic impact of radiotherapy dose to the axilla in cN + /ypN0 breast cancer after primary systemic therapy and sentinel lymph node biopsy: toward true de-escalation of axillary management.","authors":"Tae Hoon Lee, Won Kyung Cho, Hyebin Lee, Tae Gyu Kim, Hyunju Shin, Sang Hee Ahn, Won Park, Heerim Nam, Haeyoung Kim","doi":"10.1007/s12282-026-01879-8","DOIUrl":"10.1007/s12282-026-01879-8","url":null,"abstract":"<p><strong>Background: </strong>The optimal extent of axillary radiotherapy in patients with clinically node-positive (cN +) breast cancer who became node-negative on sentinel lymph node biopsy (SLNB) (ypN0 by SLNB) after primary systemic therapy (PST) remains uncertain. While de-escalated axillary surgery has been widely adopted, evidence guiding the necessity and dose of axillary irradiation, particularly to initially involved nodes (ALN_inv), is limited.</p><p><strong>Methods: </strong>We retrospectively analyzed 132 patients with cN1-2a breast cancer treated at three institutions between 2009 and 2018. All patients underwent PST, curative breast surgery with SLNB without axillary lymph node dissection, and postoperative radiotherapy. Radiation doses to ALN_inv and axillary levels I-III were reconstructed and expressed as relative mean dose percentages (D_mean%) of the prescribed breast/chest wall dose. Oncologic outcomes were evaluated using Kaplan-Meier and Cox regression analyses.</p><p><strong>Results: </strong>The median D_mean% values were 91.4% for ALN_inv, 69.5% for level I, 82.9% for level II, and 94.8% for level III. After a median follow-up of 79.0 months, 15 patients (11.4%) developed recurrence, including three axillary recurrences (2.3%), corresponding to a 5-year axillary recurrence-free survival of 98.4%. The 5-year DFS and OS rates were 90.1% and 96.2%, respectively. No clear association was observed between axillary dose and DFS, whereas non-pathologic complete response (HR 3.781, 95% CI 1.055-13.550, p = 0.041) and total mastectomy (HR 4.433, 95% CI 1.535-12.800, p = 0.006) were independently associated with worse DFS.</p><p><strong>Conclusion: </strong>In cN + /ypN0 breast cancer patients treated with PST and SLNB, favorable axillary control and DFS were achieved even with relatively low radiation doses to ALN. No clear association was observed between delivered axillary dose and oncologic outcomes, suggesting the feasibility of tailored de-escalation of axillary radiotherapy. Further prospective studies are necessary to define safe dose thresholds and target volumes.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"1047-1058"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148311159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic mammoplasty in selected East Asian patients: oncologic safety and cosmetic outcomes.","authors":"Ryohei Katsuragi, Hisamitsu Zaha, Norie Abe, Shunichiro Orihara, Maho Okiyama, Ayako Koki, Toshihiko Satake","doi":"10.1007/s12282-026-01897-6","DOIUrl":"10.1007/s12282-026-01897-6","url":null,"abstract":"<p><strong>Background: </strong> Therapeutic mammoplasty (TM) is a well-established oncoplastic breast-conserving technique, particularly for patients with large ptotic breasts. However, evidence on the oncologic safety and cosmetic outcomes in East Asian patients who meet these anatomical criteria remains limited. This study evaluated the outcomes of TM combined with contralateral reduction mammoplasty in a cohort of East Asians.</p><p><strong>Methods: </strong> We conducted a single-center retrospective observational study of consecutive patients who underwent TM with simultaneous contralateral reduction mammoplasty for breast cancer between April 2014 and March 2024. The primary endpoint was oncologic safety, assessed using the positive margin rate and local recurrence. The secondary endpoints included 1-year cosmetic outcomes, assessed using BCCT.core and the Harvard scale by blinded physicians.</p><p><strong>Results: </strong>A total of 104 patients were included (mean age: 59.6 ± 10.6 years, mean body mass index: 28.4 ± 5.1 kg/m², mean tumor size: 22.0 ± 11.5 mm). Positive margins occurred in 5 patients; 4 underwent additional resection and 1 received boost irradiation alone. At a median follow-up of 58.6 months, no local recurrence occurred, whereas distant recurrence occurred in 1 patient. Perioperative complications occurred in 27 patients, with 6 requiring reoperation; no cases of nipple necrosis were reported. Among 100 evaluable patients, excellent or good cosmetic outcomes were achieved in 83.0% and 79.0% according to BCCT.core and the Harvard scale, respectively. Boost irradiation and perioperative chemotherapy were associated with poor cosmetic outcomes.</p><p><strong>Conclusions: </strong> In selected East Asian patients with relatively large ptotic breasts, TM combined with contralateral reduction mammoplasty demonstrated favorable oncologic safety and cosmetic outcomes.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"1194-1205"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148633520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interpretable machine-learning survival prediction of breast cancer prognosis from lifestyle factors: evidence from UK biobank.","authors":"Yishan Yao, Xiaobing Zhai, Zhichao Liang, Chi Kin Lam, Hui Xie, Henry H Y Tong, Tong Tong, Yan Chen, Ritse M Mann, Muzhen He, Kefeng Li, Tao Tan","doi":"10.1007/s12282-026-01893-w","DOIUrl":"10.1007/s12282-026-01893-w","url":null,"abstract":"<p><strong>Background: </strong>Understanding how lifestyle habits influence breast cancer survival is crucial for improving long-term outcomes and guiding individualized care. The purpose of this study is to comprehensively understand how dietary habits, exercise frequency, sleep quality and the frequency of tobacco and alcohol use affect the survival of breast cancer patients by analyzing the synergistic effects of multiple lifestyle habits.</p><p><strong>Methods: </strong>We analyzed data from 21,219 female breast cancer patients in the UK Biobank, a large-scale population-based cohort. Three feature selection methods were applied to identify key prognostic variables. Five survival risk models were compared to investigate the relationship between breast cancer survival and lifestyle habits. Kaplan-Meier survival analysis and SHapley Additive exPlanations (SHAP) interpretability analysis were performed on risk scores calculated from the best-performing model.</p><p><strong>Results: </strong>Through feature selection, we identified that age, Body Mass Index (BMI), smoking status, and treatment pill intake were pinpointed as critical characteristics influencing the survival of breast cancer patients. Among all models, the eXtreme Gradient Boosting (XGBoost) model demonstrated the highest predictive performance (3 years: AUC = 0.748, 6 years: AUC = 0.749, 9 years: AUC = 0.765). Kaplan-Meier analysis showed that patients classified as high-risk based on the median risk score had significantly worse survival outcomes (P < 0.0001). SHAP analysis further confirmed the dominant influence of key characteristics on mortality risk.</p><p><strong>Conclusions: </strong>This study highlights the prognostic value of lifestyle habits in breast cancer survival. By integrating routine health indicators into interpretable machine learning models, our findings provide a practical foundation for individualized risk assessment and lifestyle-based intervention strategies.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"1147-1159"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148475542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}